Bolt Biotherapeutics Inc.

12/06/2021 | Press release | Distributed by Public on 12/06/2021 05:05

Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress[...]